A0A6D2Y4Q4 (A0A6D2Y4Q4_PANTR) Pan troglodytes (Chimpanzee)

NAD-dependent protein deacetylase UniProtKBInterProInteractive Modelling

389 aa; Sequence (Fasta) ; 3 identical sequences: Homo sapiens: Q8IXJ6; Pan troglodytes: K7BWL3; Gorilla gorilla gorilla: G3QJ69

Available Structures

50 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Sirt2 in complex with a 13-mer trifluoroacetylated Ran peptide Heteromer
P62826; Q8IXJ6;
56-356
100.0SO4;ZN;
Human SIRT2 in complex with myristoylated peptide (H3K9myr) Heteromer
P68431; Q8IXJ6;
56-355
100.0ZN;
Human SIRT2 in complex with 2-O-myristoyl-ADP-ribose Heteromer
Q8IXJ6;
56-355
100ZN;OMR;
Human SIRT2 in complex with myristoylated peptide (TNF-alphaK20myr) Heteromer
P01375; Q8IXJ6;
57-355
100.0ZN;
Crystal structure of SIRT2 with FAM-PEG4-H4K16(myristoyl) peptide Heteromer
P62805; Q8IXJ6;
57-355
100.0ZN;MYR;
Crystal structure of Sirt2-ADPR at an improved resolutionhomo-2-mer55-355
100ZN;AR6;PGE;
Human SIRT2 in complex with small molecule 359homo-2-mer56-356
100.0ZN;SO4;EDO;DMS;E7K;
Crystal structure of human Sirt2 in complex with a brominated 2nd generation SirReal inhibitor and …homo-2-mer56-356
100.0ZN;5GN;NAD;
Crystal structure of human Sirt2 in complex with a SirReal probe fragmenthomo-2-mer56-356
100.0ZN;5GR;EDO;EPE;BU3;
Structure of human Sirtuin 2 in complex with a selective thienopyrimidinone based inhibitorhomo-2-mer56-356
100.0ZN;7KJ; 14×SO4;PG4;P6G;
Structure of human SIRT2 in complex with ADP-ribosehomo-2-mer55-355
100.0ZN;ACT;AR6;GOL;PGE;
Crystal structure of human Sirt2 in complex with ADPR and EX-243homo-2-mer56-355
100ZN;AR6;OCZ;PEG;
Human Sirt2 in complex with ADP ribose and nicotinamidehomo-2-mer56-355
100AR6;NCA;PEG;EDO;NA;ZN;PGE;
Crystal structure of human Sirt2 in complex with ADPR and CHIC35homo-2-mer56-355
100ZN;AR6;4I5;
SIRT2(56-356) with covalent intermediate between mechanism-based inhibitor Glucose-TM-1beta and 1'-…homo-2-mer56-355
100.0ZN;KXJ;KXG;NA;SO4;GOL;
Re-refined structure of the human Sirt2 apoformmonomer34-356
99.68ZN;P6G;PGE;EDO;
HUMAN SIRT2 HISTONE DEACETYLASEmonomer34-356
100.0ZN;
Crystal structure of human Sirtuin 2 in complex with a selective inhibitormonomer34-356
100.0ZN;8NO;
Sirt2 in complex with a myristoyl peptidemonomer52-355
100.0ZN;EDO;3Y0;
Sirt2 in complex with a myristoyl peptidemonomer52-355
100.0ZN;EDO;CNA;3LX;
Sirtuin 2 protein with H3K18 myristoylated peptide and intact NAD moleculemonomer52-355
99.66ZN;NAD;3LX;
Sirtuin 2 demyristoylation native intermediate I & II mixturemonomer53-355
100.0NCA;YOY;YDD;
Human SIRT2 catalyse short chain fatty acyl lysinemonomer54-355
100.0ZN;CNA;
Crystal Structure of SIRT2 in complex with the macrocyclic peptide S2iL5monomer55-356
100.0ZN;MES;
Human Sirt2 in complex with SirReal2 and Ac-Lys-H3 peptidemonomer56-356
100.0ZN;3TE;
Crystal structure of Sirt2 in complex with selective inhibitor L5Cmonomer56-356
100.0ZN;L5C;
Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-5 and NAD+monomer56-356
100.0ZN;EDO;NAD;WU3;
Crystal structure of Sirt2 in complex with selective inhibitor L55monomer56-356
100.0ZN;L55;PEG;
Crystal structure of Sirt2 in complex with selective inhibitor A2Imonomer56-356
100.0A2I;ZN;BME;
Crystal structure of human Sirt2 in complex with a triazole-based SirRealmonomer56-356
100.0KZU;EDO;BTB;BU3;ZN;CL;
Crystal structure of Sirt2 in complex with selective inhibitor A29monomer56-356
100.0ZN;A2X;BME;
Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-3monomer56-356
100.0ZN;PEG;EDO;WWE;
Human Sirt2 in complex with SirReal2 and NAD+monomer56-356
100.0ZN;3TE;NAD;
Human SIRT2 in complex with a specific inhibitor, NPD11033monomer56-356
100.0ZN;8K9;
Human SIRT2 crystal structure in complex with BHJH-TM1monomer55-355
100.0ZN;3LX;
Human Sirt2 in complex with SirReal1 and Ac-Lys-OTC peptidemonomer56-355
100.0ZN;3TK;
Crystal structure of human Sirt2 in complex with the peptide-based pseudo-inhibitor TNFn-4.1monomer56-355
100.0ZN;BU3;EDO;WH8;WGN;
Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-6 and NAD+monomer57-356
100.0ZN;EDO;BTB;DMS;BU3;PGE;NAD;WU8;
Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-5monomer56-355
100.0ZN;EDO;WU3;
Crystal structure of human Sirt2 in complex with a 1,2,4-oxadiazole based inhibitormonomer56-355
100.0ZN;I1R;BTB;EDO;
Crystal structure of human Sirt2 in complex with a TNFa-Myr analogue TNFn-34monomer56-355
100.0ZN;WWK;
Human SIRT2 in complex with myristoyl thiourea inhibitor, No.13monomer56-355
100.0ZN;F4R;
Human SIRT2 in complex with myristoyl thiourea inhibitor, No.23monomer56-355
100.0ZN;F4R;
Sirtuin 2 protein with H3K18 myristoylated peptidemonomer56-355
99.65ZN;MYR;
Structure of human SIRT2 in complex with 1,2,4-Oxadiazole inhibitor and ADP ribose.monomer56-355
100ZN;AR6;7KE;EDO;DMS;GOL;
Crystal structure of human Sirt2 without Sirt2-specific insertionmonomer56-355
100.0ZN;
Sirtuin 2 demyristoylation native final productmonomer56-355
100.0OMR;ZN;
Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-6monomer57-355
100.0ZN;EDO;BTB;BU3;WU8;
Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-3 and NAD+monomer57-355
100.0ZN;NAD;EDO;WWE;
Human Sirt2 in complex with ADP-ribose and the inhibitor quercetinmonomer57-355
100ZN;AR6;QUE;

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3zgo.1.Amonomer0.8134-355
ZN;99.69
5y5n.1.Amonomer0.7834-355
ZN;8NO;99.07